AstraZeneca 2007.

Study characteristics
Methods	8‐week trial with 2 arms: quetiapine fumarate placebo Duration of trial: 8 weeks + 10 weeks follow‐up Country: The Netherlands Setting: no information
Participants	Methods of recruitment of patients: no information Overall sample size: 24 Diagnosis of borderline personality disorder: DSM‐IV Means of assessment: SCID‐II Mean age: no information Sex: no information Comorbidity: no information Inclusion criteria BPD according to DSM‐IV, including criterion 9: transient, stress‐related paranoid ideation or severe dissociative symptoms Aged 18‐55 years In‐ or outpatients Exclusion criteria Depressive disorder Bipolar disorder Schizoaffective disorder/schizophrenia/delusional disorder/schizotypal personality disorder Alcohol or substance dependence quetiapine doses > 100 mg od use in the past History of trauma capitis Visual and auditive disorders Neurological disorders (epilepsy) Pregnancy No adequate contraception History of cardial complaints/cardiological disorder Known sensitivity for quetiapine
Interventions	Experimental group Treatment name: quetiapine fumarate Number randomised to group: 13 Duration: 8 weeks Control/comparison group Comparison name: placebo Number randomised to group: 11 Duration: 8 weeks Both groups Concomitant psychotherapy: no information Concomitant pharmacotherapy: not allowed, except for SSRIs and benzodiazepines, with doses stabilised 8 weeks before start of trial period Proportions of participants taking standing medication during trial observation period: no information
Outcomes	Primary outcomes: none Secondary outcomes Dissociation and psychotic‐like symptoms, measured by the BPRS, PANSS and the Dissociation Questionnaire (DIS‐Q). Assessed at baseline and at 1, 2, 4, 6 and 8 weeks Attrition, measured in terms of patients lost after randomisation in each group
Notes	Sample size calculation: no information Ethic approval: no information Funding source: funded or partially funded by pharmaceutical industry Conflicts of interest: The trial director is affiliated with AstraZeneca who produces the medication tested. Comments from review authors (limitations) Small sample, underpowered Key trial dates are a considerable duration of time apart
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: no information
Allocation concealment (selection bias)	Unclear risk	Comment: no information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: Trial registration stated that the study had triple blinding (participant, care provider and investigator), however, there was no information on how the blinding was secured or if it was adequately maintained throughout the study to permit a judgement of low or high risk of bias.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: Trial registration stated that the study had triple blinding (participant, care provider and investigator), however, there was no information on how the blinding was secured or if it was adequately maintained throughout the study to permit a judgement of low or high risk of bias.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: dropout 5/13 in experimental intervention and 3/11 in placebo group. No information on reasons for dropout or imputation method
Selective reporting (reporting bias)	High risk	Comment: The protocol mentioned psychotic‐like symptoms and severity of psychiatric symptoms + mood, anger, impulsiveness, hostility and anxiety in patients with BPD. Only psychotic and dissociative symptoms were reported.
Vested Interest (funding and/or author affiliations)	High risk	Comment: Trial director is from AstraZeneca and the medication tested is from AstraZeneca.
Other bias	Low risk	Comment: no indication of other bias